Starpharma Holdings Ltd
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology.
The business
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Starpharma Boosts Stake in Petalion Therapeutics to Lead Dendrimer-Enhanced Oncology Program
Starpharma lifts its Petalion stake to 66%, taking control of the FAP-targeted cancer program and committing up to $5m to advance development.
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]
Starpharma Partners with Genentech to Develop Innovative Cancer Therapies Using DEP Technology
Starpharma Holdings (ASX: SPL) has signed a collaboration and licence agreement with US-based company Genentech to develop innovative cancer therapies leveraging Starpharma’s proprietary DEP (dendrimer-enhanced product) drug delivery platform. Dendrimers are precise, synthetically-manufactured molecules with unique properties – including size, structure, a high degree of branching, polyvalency, and water solubility – that can be advantageous […]
Starpharma’s DEP irinotecan shows promising efficacy in Phase 2 advanced cancer trials
Starpharma (ASX: SPL) has announced positive anti-tumour efficacy results from a Phase 2 clinical trial of its lead candidate DEP irinotecan in heavily pre-treated patients with a range of difficult-to-treat advanced and metastatic cancers. DEP irinotecan is a novel patented nanoparticle formulation of SN38, the active metabolite of the widely-used anti-cancer drug irinotecan (marketed as […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.